produits : TG4001 teaser


Target HPV-induced cancers (HPV-16, E6 & E7 + IL-2)

TG4001, an innovative therapy capable of combating papillomavirus-induced cancers. The concept behind TG4001 is to teach the immune system to recognise and destroy the cancer cells expressing HPV-16 antigens, specifically E6 and E7 antigens.

We have selected typical papillomavirus sequences that code for these antigens and have incorporated them into the DNA of another virus (the MVA virus) previously rendered harmless. We have also introduced a gene that codes for a molecule (interleukin 2, IL-2) that will stimulate the immune system at the injection site.

TG4001 triggers a specific immune response that supports the recognition and destruction of cancer cells carrying the HPV viral antigens. This approach enables the body to destroy the tumours.

Based on promising Phase Ib/II data, Transgene is conducting a randomized Phase II trial of TG4001 in combination with avelumab. This study is being conducted with the alliance of Merck KGaA, Darmstadt, Germany, and Pfizer, which is supplying avelumab.

TG4001 in action

More information

Transgene sa
400 Boulevard Gonthier d’Andernach - Parc d'Innovation - CS80166
67405 Illkirch Graffenstaden Cedex - France |
Tel. : + 33 (0) 3 88 27 91 00


© 2021 Transgene - All rights reserved
Terms of use - Credits